Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether fostamatinib, a drug that blocks activated B
cells will be effective in preventing and treating chronic graft vs host disease (cGVHD)
after allogeneic stem cell transplant. Activated B cells may play a role in development of
cGVHD. Inhibiting the B cell activation using fostamatinib after allogeneic stem cell
transplant may prevent the development of cGVHD.